East Sussex Healthcare
NHS Trust

Eastbourne District General Hospital
Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FOI REF: 26/738

11th November 2026

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I would be grateful if you could tell me how many patients were treated in the 3 months between July and September 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

1. **How many patients were treated in total regardless of diagnosis with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?**

Drug Name	Total number of patients treated regardless of diagnosis
Adalimumab	909
Abrocitinib	1
Apremilast	7
Baricitinib	0
Bimekizumab	59
Brodalumab	19
Certolizumab Pegol	5
Deucravacitinib	2
Dupilumab	147
Etanercept	219
Guselkumab	39
Icotrokinra	0
Infliximab	263
Ixekizumab	10
Lebrikizumab	0
Nemolizumab	6
Risankizumab	49
Secukinumab	151
Tildrakizumab	1

Drug Name	Total number of patients treated regardless of diagnosis
Tralokinumab	8
Ustekinumab	342

2. How many patients were treated by the Dermatology Department with the following drugs between 1st July 2026 and 30th September 2026?

Drug Name	Number of patients treated by the Dermatology Department
Adalimumab	0
Apremilast	4
Baricitinib	0
Bimekizumab	7
Brodalumab	19
Certolizumab Pegol	3
Dupilumab	137
Etanercept	1
Guselkumab	8
Infliximab	1
Ixekizumab	7
Omalizumab	0
Risankizumab	13
Secukinumab	12
Upadacitinib	12
Ustekinumab	109

3. How many patients with Plaque Psoriasis across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with
Adalimumab	0
Apremilast	3
Bimekizumab	1
Brodalumab	0
Certolizumab Pegol	2
Etanercept	0
Guselkumab	0
Infliximab	0
Ixekizumab	3
Risankizumab	0
Secukinumab	15
Ustekinumab	24

4. **How many patients with Atopic Dermatitis across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?**

Drug Name	Number Patients Atopic Dermatitis
Baricitinib	0
Dupilumab	135
Nemolizumab	6
Upadacitinib	11

5. **How many patients with Hidradenitis Suppurativa across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?**

Drug Name	Number Patients Hidradenitis Suppurativa
Adalimumab	1
Bimekizumab	0
Secukinumab	0

6. **How many patients with Chronic Spontaneous Urticaria across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?**

Drug Name	Number Patients Chronic Spontaneous Urticaria
Dupilumab	0
Omalizumab	1
Remibrutinib	0

I am conducting analysis on the use of biologic medicines in secondary care and kindly request your help.

I would be grateful if you could respond with the number of patients treated with specific medicines between the start of July 2026 and the end of September 2026, or the latest three-month period for which data is available. Please include data for all hospitals in your organisation.

7. **How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2026 and the end of September 2026?**

Name of medicine	Number patients treated
Benralizumab (Fasenra)	0
Depemokimab (Exdensur)	0

Name of medicine	Number patients treated
Dupilumab (Dupixent)	147
Lebrikizumab (Ebglyss)	0
Mepolizumab (Nucala)	0
Omalizumab (Xolair)	20
Reslizumab (Cinqaero)	49
Tezepelumab (Tezspire)	0

8. **How many patients were treated for severe asthma, COPD, CRwNP with the following medicines in the 3 months between the start of July 2026 and the end of September 2026?**

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic Obstructive Pulmonary Disease (COPD)	Chronic rhinosinusitis with nasal polyps (CRwNP)
Benralizumab (Fasenra)	0		
Depemokimab (Exdensur)	0		0
Dupilumab (Dupixent)	1	1	0
Mepolizumab (Nucala)	0	0	0
Omalizumab (Xolair)	2		0
Reslizumab (Cinqaero)	0		
Tezepelumab (Tezspire)	0		0

9. **How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2026 and the end of September 2026?**

Name of medicine	Respiratory departments	Dermatology departments	Other departments
Benralizumab (Fasenra)	0	0	0
Depemokimab (Exdensur)	0	0	0
Dupilumab (Dupixent)	0	137	10
Mepolizumab (Nucala)	0	0	0

Name of medicine	Respiratory departments	Dermatology departments	Other departments
Omalizumab (Xolair)	0	19	1
Reslizumab (Cinqaero)	0	0	0
Tezepelumab (Tezspire)	0	0	0

10. How many patients with the following diagnoses were treated with Dupilumab in the 3 months between the start of July 2026 and the end of September 2026?

Diagnoses for Asthma-COPD Overlap Syndrome	ICD-10 or SNOMED CT codes	Patients
Other chronic obstructive pulmonary disease	J44*	0
Other specified chronic obstructive pulmonary disease	J44.8	0
Other specified chronic obstructive pulmonary disease	J44.89	0
Asthma-chronic obstructive pulmonary disease overlap syndrome	10692761000119107	0
Acute exacerbation of chronic obstructive pulmonary disease with asthma	1751000119100	0
Chronic asthma with fixed airflow obstruction	866881000000101	0
Chronic asthmatic bronchitis	195949008	0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm